| Literature DB >> 27596095 |
David G Twigg1, Noriyasu Kondo1,2, Sophie L Mitchell1, Warren R J D Galloway1, Hannah F Sore1, Andrew Madin3, David R Spring4.
Abstract
Fragment-based lead generation has proven to be an effective means of identifying high-quality lead compounds for drug discovery programs. However, the fragment screening sets often used are principally comprised of sp(2) -rich aromatic compounds, which limits the structural (and hence biological) diversity of the library. Herein, we describe strategies for the synthesis of a series of partially saturated bicyclic heteroaromatic scaffolds with enhanced sp(3) character. Subsequent derivatization led to a fragment collection featuring regio- and stereo-controlled introduction of substituents on the saturated ring system, often with formation of new stereocenters.Entities:
Keywords: drug design; drug discovery; fused-ring systems; nitrogen heterocycles; synthetic methods
Year: 2016 PMID: 27596095 PMCID: PMC5091628 DOI: 10.1002/anie.201606496
Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN: 1433-7851 Impact factor: 15.336
Figure 1Selected examples of bioactive compounds containing functionalized partially saturated bicyclic heteroaromatics (highlighted in red).
Scheme 1General synthetic strategy toward PSBH scaffolds 1 and subsequent incorporation of new functionalities (2) or rings (3).
Synthesis of pyrazole‐based PSBH scaffolds.
| Step | |||||||
|---|---|---|---|---|---|---|---|
| m | R | X | A ( | B ( | C ( | D ( | |
|
| 0 | H |
| 85 %[a] | 80 % | 55 % | 45 %[h] |
|
| 0 | H |
| – | – | 86 % | 84 % |
|
| 0 | H |
| – | – | 55 % | 89 % |
|
| 0 | H |
| – | – | 59 %[e] | 65 % |
|
| 0 | H |
| – | – | 29 %[f] | 83 % |
|
| 0 | Me |
| 76 %[a] | 69 % | 44 % | 90 % |
|
| 1 | H |
| 61 %[b] | 82 % | 70 % | 93 % |
|
| 1 | H |
| – | – | 36 % | 59 %[h] |
Reaction conditions: [a] R′‐BF3K (1.5 equiv), Pd(dppf)Cl2⋅CH2Cl2 (5 mol %), K2CO3 (3.0 equiv), THF/H2O, 70 °C. [b] 5 (1.0 equiv), LDA (1.2 equiv), CuBr (20 mol %), allyl bromide (1.2 equiv), THF, −78 °C to RT. [c] TFA, CH2Cl2, RT. [d] NaH (1.5 equiv), alkyl bromide (1.5 equiv), THF or DMF, 70 °C. [e] NaH (1.5 equiv), 11 (1.5 equiv), THF, 70 °C. [f] 12 (2.0 equiv), K2CO3 (3.0 equiv), DMF, RT, 43 %; then NaH (1.5 equiv), allyl iodide (1.5 equiv), DMF, RT, 68 %. [g] Grubbs II (10 mol %), CH2Cl2, 40 °C. [h] Hoveyda‐Grubbs II (10 mol %), toluene, 110 °C or CH2Cl2, RT. THF=tetrahydrofuran, TFA=trifluoroacetic acid, DMF=N,N‐dimethylformamide.
Synthesis of pyridine‐based PSBH scaffolds.
| Step | |||||||
|---|---|---|---|---|---|---|---|
| R | n | R1 | R2 | A ( | B ( | C ( | |
|
| Boc2N | 0 | H | H | 85 % | 60 % | 95 % |
|
| Boc2N | 0 | H | Me | – | 69 % | 94 % |
|
| Boc2N | 0 | H | CF3 | – | 77 % | 54 % |
|
| Boc2N | 0 | Me | H | 87 % | 60 % | 94 % |
|
| Boc2N | 0 | Ph | H | 92 % | 68 % | 83 % |
|
| Boc2N | 1 | H | H | 78 %[c] | 41 % | 65 % |
|
| Cl | 1 | H | H | 73 %[d] | 79 % | 91 % |
Reaction conditions: [a] Boc2O (2.5 equiv), DMAP (0.1 equiv), THF, 70 °C. [b] R′‐BF3K or R′‐B(MIDA) (1.5 equiv), Pd(dppf)Cl2⋅CH2Cl2 (10 mol %), K2CO3 (3.0 equiv), THF/H2O, 70 °C. [c] Allyltributyltin (1.1 equiv), Pd(PPh3)4 (10 mol %), KF (2 equiv), toluene, 110 °C. [d] i‐PrMgCl.LiCl (1.5 equiv), allyl bromide (1.2 equiv), THF, −15 °C to RT. [e] LDA (1.2 equiv), alkyl bromide (1.5 equiv), THF, −78 °C to RT. [f] Grubbs II (5 mol %), CH2Cl2, 40 °C. DMAP=4‐dimethylaminopyridine.
Scheme 2Functionalization of PSBH scaffolds. For reaction conditions, see the Supporting Information.
Mean physicochemical properties of fragment collections.
| Property[a] | Ideal Range[b] | This work | Chembridge | Maybridge |
|---|---|---|---|---|
|
| ||||
[a] MW=molecular weight, PSA=polar surface area, HBA=number of hydrogen‐bond acceptors, HBD=number of hydrogen‐bond donors, HAC=heavy atom count, RBC=rotatable bond count. [b] Based on the guidelines used by Astex Pharmaceuticals.14, 21 Green: within ideal range, orange: at extreme of ideal range, red: outside ideal range. See the Supporting Information for further details.